![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 292, Issue 1, 415-424, January 2000
Institut National de la Santé et de la Recherche
Médicale, Physiopathologie Cardiovasculaire, CHU Arnaud de
Villeneuve (F.A., L.B., O.K.C., P.L., G.V.), Montpellier ; Service
de Cardiologie CHU Arnaud de Villeneuve (J.-M.D.), Montpellier; and
Sanofi Recherches (P.G., D.N.), Montpellier, France
We studied the effects of dronedarone (SR 33589) on the action
potentials, membrane ionic currents, and arrhythmic activity in control
rats and in rats after myocardial infarction, a model known to develop
anomalous electrical activity. Dronedarone increased action potential
duration in normal hearts. It had little effect on the action
potentials that were already prolonged in the postmyocardial infarcted
(PMI) rats. Particularly, dronedarone reduced the late sustained
K+ current, IK (or Isus) by
69%. Dronedarone induced only a tonic block of
IK. Similar relative inhibitions of
IK by dronedarone were obtained in young,
sham, and PMI rats, even if IK was less in
sham than in young and further reduced in PMI rats. The
EC50 values were 0.78 and 0.85 µM in sham and PMI rats.
Dronedarone induced a weak increase in the fast transient outward
current, Ito. Time-to-peak and inactivation
time constant of Ito were decreased by
dronedarone that also induced a marked slowing of
Ito recovery from inactivation. Similar
effects were observed on the reduced Ito
recorded in PMI rats. Holter monitoring study in control, unthetered
animals showed that dronedarone had no proarrhythmic effect. On rats,
which after myocardial infarction exhibited ventricular premature
beats, dronedarone significantly decreased beat occurrence during the
7-day treatment; this effect was sustained for two more weeks. Thus,
dronedarone exerts antiarrhythmic effects on PMI rat heart. Its effects
are attributable for the most part to the inhibition of outward
K+ currents and the increase in effective refractory period.
This article has been cited by other articles:
![]() |
K. M Dale and C M. White Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter Ann. Pharmacother., April 1, 2007; 41(4): 599 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Tafreshi and J. Rowles A Review of the Investigational Antiarrhythmic Agent Dronedarone Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 15 - 26. [Abstract] [PDF] |
||||
![]() |
N. Wadhani, J. S. Sarma, B. N. Singh, D. Radzik, and C. Gaud Dose-Dependent Effects of Oral Dronedarone on the Circadian Variation of RR and QT Intervals in Healthy Subjects: Implications for Antiarrhythmic Actions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 184 - 190. [Abstract] [PDF] |
||||
![]() |
P. Kirchhof, H. Degen, M. R. Franz, L. Eckardt, L. Fabritz, P. Milberg, S. Laer, J. Neumann, G. Breithardt, and W. Haverkamp Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 257 - 263. [Abstract] [Full Text] |
||||
![]() |
A. D Pitt, C. Fernandes, N. L Bewick, P. D Hemsworth, K. A Buhagiar, P. S Hansen, H. H Rasmussen, L. Delbridge, and D. W Whalley Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone Cardiovasc Res, January 1, 2003; 57(1): 101 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Singh and J. S. M. Sarma Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 69 - 87. [PDF] |
||||